Table 2.
Multivariable Model Results for Mean Reduction in UUI Episodes Over 6 Months
| Outcome: Reduction in UUI Episodes Over 6 Months | |||||
|---|---|---|---|---|---|
|
| |||||
| Predictor | ≥ 65 years Adjusted Coefficient (95% CI) N=191 | ≥ 65 years Adjusted Coefficient (95% CI) N=173 | PredictorMain Effect p-value | Predictor x Age Interaction p-value | Predictor x Treatment Interaction p-value |
|
| |||||
| Age ≥ 65a,b | |||||
| OnabotulinumtoxinA (N=100) | −0.1 (−1.233, 0.979) | Reference | 0.821 | — | 0.148 |
| Neuromodulation (N=91) | −0.698 (−1.832, 0.437) | Reference | 0.227 | ||
|
| |||||
| HUI-3 (per 0.3 ptsc) | 0.537 (0.266,0.808) | 0.111 (−0.188,0.410) | 0.002 | — | — |
|
| |||||
| UUI episodes at baseline | 0.621 (0.540, 0.702) | ≥0.001 | — | — | |
a
Age category and an age-category-by-treatment-group interaction term were included in the multivariable model irrespective of p-value. For other predictors and interactions, terms were selected by backwards selection subject to p ≥ 0.1, as described in Methods. Coefficient estimates represent the mean daily reduction in UUIE episodes associated with a unit increase in the predictor.
b
Age ≥ 65, onabotulinumtoxinA N=100 and neuromodulation N=91. Age ≥ 65, onabotulinum toxin N=90, neuromodulation N=83
c
HUI-3 baseline standard deviation in our study population
d
Multivariable linear mixed model used for analysis